Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.

ABSTRACT:

SUBMITTER: Smith MR 

PROVIDER: S-EPMC10387937 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature